Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Cardiac fibrosis is central to the pathology of heart failure, particularly heart failure with preserved ejection fraction (HFpEF). Irrespective of the underlying profibrotic condition (e.g. ageing, diabetes, hypertension), maladaptive cardiac fibrosis is defined by the transformation of resident fibroblasts to matrix-secreting myofibroblasts. Numerous profibrotic factors have been identified at the molecular level (e.g. TGFβ, IL11, AngII), which activate gene expression programs for myofibroblast activation. A number of existing HF therapies indirectly target fibrotic pathways; however, despite multiple clinical trials in HFpEF, a specific clinically effective antifibrotic therapy remains elusive. Therapeutic inhibition of TGFβ, the master-regulator of fibrosis, has unfortunately proven toxic and ineffective in clinical trials to date, and new approaches are needed. In this review, we discuss the pathophysiology and clinical implications of interstitial fibrosis in HFpEF. We provide an overview of trials targeting fibrosis in HFpEF to date and discuss the promise of potential new therapeutic approaches and targets in the context of underlying molecular mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 1×
“This has subsequently been confirmed to be a class effect in alternative SGLT2 inhibitor trials (Neal et al, 2017; McMurray et al, 2019), and much interest has since surrounded the use of these drugs in the management of fibrosis and HFpEF, with or without comorbid diabetes mellitus.”
BackgroundDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · cited 1×
“Clinical trials of the ARB—neprilysin inhibitor (ARNI) combination of valsartan and sacubitril, have demonstrated significant efficacy in reducing symptoms, hospitalization and mortality in HFrEF in addition to standard therapy, including RAAS inhibition (McMurray et al, 2014).”
BackgroundPfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Myofibroblasts exhibit two cardinal features: firstly, they secrete large amounts of ECM components, and secondly, via the expression of smooth muscle actin (SMA, otherwise known as ACTA2), they are contractile (Wynn, 2008; Rosenbloom et al, 2017).”
BackgroundA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975 · cited 1×
“…Treatment of idiopathic pulmonary fibrosis (IPF) has been transformed by the use of the small molecule inhibitors pirfenidone and nintedanib (King et al, 2014; Flaherty et al, 2019), and tranilast has been used in the treatment of asthma and keloid scars for over 30 years in Japan…”
BackgroundChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“CAR-T therapy has been used effectively in the clinic to treat B-cell leukaemias and lymphomas resistant to standard therapy by targeting CD19-positive cells (Porter et al, 2011; Schuster et al, 2017; Park et al, 2018).”
BackgroundA Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 1×
“In contrast, IL11 exerts its main effects in human and mouse fibroblasts at the post-transcriptional level, via sustained activation of the non-canonical ERK signalling pathway, with little evidence for a role of STAT although it is mildly phosphorylated (Heinrich et al, 2003; Schafer et al, 2017).”
BackgroundCar t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · cited 1×
“The developing oncology treatment, chimeric antigen receptor T-cell (CAR-T cell) therapy, uses re-engineered cytotoxic T cells to target specifically selected surface markers to deplete a defined cell population (June et al, 2018).”
BackgroundYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809 · cited 1×
“However—as with ACE-I—rodent and intermediate phenotype studies have so far failed to translate to improved outcomes in large randomized controlled trials (RCT) of MRA in HFpEF (Edelmann et al, 2013; Pitt et al, 2014).”
BackgroundLong-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688 · cited 1×
“CAR-T therapy has been used effectively in the clinic to treat B-cell leukaemias and lymphomas resistant to standard therapy by targeting CD19-positive cells (Porter et al, 2011; Schuster et al, 2017; Park et al, 2018).”
BackgroundDirect reprogramming of fibroblasts into functional cardiomyocytes by defined factors
Ieda, M., Fu, J.-D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y., Bruneau, B. G., & Srivastava, D. (2010) · Cell · doi:10.1016/j.cell.2010.07.002 · Cited by 2,454
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430 · cited 2×
“…subgroup analysis of this trial has yielded some interesting results in particular a significant improvement in the primary outcome in women (Solomon et al, 2019) which is particularly intriguing given the high burden of HFpEF in women (Vasan et al, 2018), and this finding may stimulate…”
BackgroundResultNintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Epidemiology and risk profile of heart failure
Bui, A. L., Horwich, T. B., & Fonarow, G. C. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.165 · Cited by 2,077
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967 · cited 1×
“Mice have high embryonic lethality and those that survive to birth die between 3 and 5 week of age due to an excessive and widespread inflammatory response resulting in multiorgan failure (Shull et al, 1992; Kulkarni et al, 1993).”
BackgroundEsposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961
Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase
Li, Y., Huang, T.-T., Carlson, E. J., Melov, S., Ursell, P. C., Olson, J. L., Noble, L. J., Yoshimura, M. P., Berger, C., Chan, P. H., et al. (1995) · Nature Genetics · doi:10.1038/ng1295-376 · Cited by 1,789 · cited 1×
“Mice with transgenic knockout of the ROS scavenger, superoxide dismutase, rapidly develop cardiac fibrosis and die within 10 days of life (Li et al, 1995).”
BackgroundYu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Revisiting Cardiac Cellular Composition
Pinto, A. R., Ilinykh, A., Ivey, M. J., Kuwabara, J. T., D’Antoni, M. L., Debuque, R., Chandran, A., Wang, L., Arora, K., Rosenthal, N. A., et al. (2016) · Circulation Research · doi:10.1161/circresaha.115.307778 · Cited by 1,400 · cited 2×
“Two markers which appear to be relatively more specific to CF are the platelet-derived growth factor receptor a (PDGFRa) and the transcription factor Tcf21, both of which are expressed in the majority of myofibroblast-forming cells (Smith et al, 2011; Acharya et al, 2012; Pinto et al, 2016).”
BackgroundMyofibroblast contraction activates latent TGF-β1 from the extracellular matrix
Wipff, P.-J., Rifkin, D. B., Meister, J.-J., & Hinz, B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704042 · Cited by 1,346
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056 · cited 1×
“Nintedanib, a tyrosine kinase inhibitor, has a wide range of targets including the vascular endothelial growth factor receptor, PDGF and fibroblast growth factor receptor (Hilberg et al, 2008).”
BackgroundPerivascular Gli1+ Progenitors Are Key Contributors to Injury-Induced Organ Fibrosis
Kramann, R., Schneider, R. K., DiRocco, D. P., Machado, F., Fleig, S., Bondzie, P. A., Henderson, J. M., Ebert, B. L., & Humphreys, B. D. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2014.11.004 · Cited by 922 · cited 1×
“…a greater role for endothelial to mesenchymal transition (Endo-MT; a debated process) (Zeisberg et al, 2007; Okayama et al, 2012), fibroblastic differentiation of pericytes (Kramann et al, 2015) and infiltration of inflammatory cells (Hinglais et al, 1994; Hara et al, 2002; Nevers et al, 2017).”
Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905 · cited 8×
“TAC-mediated myocardial fibrosis is enhanced in mice by transgenic overexpression of Nox4 (Kuroda et al, 2010), and cardiomyocyte-specific KO is protective against myocardial fibrosis and left ventricular dysfunction (Kuroda et al, 2010; Zhao et al, 2015).”
BackgroundInfluentialSmad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription
Zhang, Y., Feng, X.-H., & Derynck, R. (1998) · Nature · doi:10.1038/29814 · Cited by 809 · cited 1×
“This SMAD complex translocates to the nucleus where it binds to SMAD binding elements in the genome to act as a transcription factor independently (Dennler et al, 1998; Martin-Malpartida et al, 2017) or in combination with multiple other transcription factors (Zhang et al, 1998; Mullen et al, 2011).”
BackgroundTargeting cardiac fibrosis with engineered T cells
Aghajanian, H., Kimura, T., Rurik, J. G., Hancock, A. S., Leibowitz, M. S., Li, L., Scholler, J., Monslow, J., Lo, A., Han, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1546-z · Cited by 801 · cited 2×
“A new and alternative paradigm has been to target the fibroblast itself, aiming to deplete myofibroblast populations (Aghajanian et al, 2019).”
BackgroundMethodCucoranu, I., Clempus, R., Dikalova, A., Phelan, P. J., Ariyan, S., Dikalov, S., & Sorescu, D. (2005) · Circulation Research · doi:10.1161/01.res.0000187457.24338.3d · Cited by 786 · cited 2×
“…is elevated in response to TGFb signalling (Cucoranu et al, 2005) and knockdown of NOX4 activity using siRNA or small molecule inhibitors reduces fibrosis and myofibroblasts differentiation in response to TGFb or AngII stimulation (Cucoranu et al, 2005; Chan et al, 2013; Somanna et al, 2016).”
BackgroundNADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart
Kuroda, J., Ago, T., Matsushima, S., Zhai, P., Schneider, M. D., & Sadoshima, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002178107 · Cited by 772 · cited 3×
“However, conflicting results have emerged, suggesting that pleiotropic roles of NOX4 in angiogenesis and fatty acid oxidation may be adaptive in the stressed heart and that inhibition of Nox4 may be detrimental in some contexts (Zhang et al, 2010; Nabeebaccus et al, 2017; Schnelle et al, 2019), and it may demonstrate…”
BackgroundZile, M. R., Baicu, C. F., S. Ikonomidis, J., Stroud, R. E., Nietert, P. J., Bradshaw, A. D., Slater, R., Palmer, B. M., Van Buren, P., Meyer, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013215 · Cited by 681 · cited 1×
“…with symptomatic HFpEF, extracellular fibrotic burden is more strongly correlated with diastolic dysfunction than is cardiomyocyte stiffness (Zile et al, 2015) and fibrosis is correlated with increased arrhythmias (Cho et al, 2018) hospitalization and mortality in HFpEF (Kanagala et al,…”
BackgroundWestermann, D., Lindner, D., Kasner, M., Zietsch, C., Savvatis, K., Escher, F., von Schlippenbach, J., Skurk, C., Steendijk, P., Riad, A., et al. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.931451 · Cited by 644 · cited 2×
“If persistent, inflammation can be associated with the emergence of profibrotic macrophages (Westermann et al, 2011; Peet et al, 2019) and infiltration of Th1 T cells (Nevers et al, 2017).”
BackgroundIL-11 is a crucial determinant of cardiovascular fibrosis
Schafer, S., Viswanathan, S., Widjaja, A. A., Lim, W.-W., Moreno-Moral, A., DeLaughter, D. M., Ng, B., Patone, G., Chow, K., Khin, E., et al. (2017) · Nature · doi:10.1038/nature24676 · Cited by 639
Self-citationThe origin of fibroblasts and mechanism of cardiac fibrosis
Krenning, G., Zeisberg, E. M., & Kalluri, R. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22322 · Cited by 601
Mitochondrial Energetics in the Heart in Obesity-Related Diabetes
Boudina, S., Sena, S., Theobald, H., Sheng, X., Wright, J. J., Hu, X. X., Aziz, S., Johnson, J. I., Bugger, H., Zaha, V. G., et al. (2007) · Diabetes · doi:10.2337/db07-0481 · Cited by 586
Redefining the identity of cardiac fibroblasts
Tallquist, M. D., & Molkentin, J. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.57 · Cited by 581
Ago, T., Kuroda, J., Pain, J., Fu, C., Li, H., & Sadoshima, J. (2010) · Circulation Research · doi:10.1161/circresaha.109.213116 · Cited by 506 · cited 1×
“Multiple profibrotic factors including AngII (Byrne et al, 2003; Johar et al, 2006), ET-1 (Duerrschmidt et al, 2000) and aldosterone (Johar et al, 2006) infusion as well as TAC (Kai et al, 2006; Ago et al, 2010) upregulate the activity of NOX enzymes resulting in increased ROS production in mice.”
BackgroundAcharya, A., Baek, S. T., Huang, G., Eskiocak, B., Goetsch, S., Sung, C. Y., Banfi, S., Sauer, M. F., Olsen, G. S., Duffield, J. S., et al. (2012) · Development · doi:10.1242/dev.079970 · Cited by 498 · cited 4×
“…have found that resident cardiac fibroblasts (CF) in the myocardium are the most significant contributor to the myofibroblasts population in cardiac injury with minimal input from extracardiac sources or endothelial structures (Acharya et al, 2012; Moore-Morris et al, 2014; Kanisicak et al, 2016).”
BackgroundMethodInfluentialClinical Phenogroups in Heart Failure With Preserved Ejection Fraction
Cohen, J. B., Schrauben, S. J., Zhao, L., Basso, M. D., Cvijic, M. E., Li, Z., Yarde, M., Wang, Z., Bhattacharya, P. T., Chirinos, D. A., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2019.09.009 · Cited by 432
Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77958 · Cited by 351
Smith, C. L., Baek, S. T., Sung, C. Y., & Tallquist, M. D. (2011) · Circulation Research · doi:10.1161/circresaha.110.235531 · Cited by 339
Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Ng, B., Dong, J., D’Agostino, G., Viswanathan, S., Widjaja, A. A., Lim, W.-W., Ko, N. S. J., Tan, J., Chothani, S. P., Huang, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1237 · Cited by 314
Self-citationPirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017) · European Respiratory Review · doi:10.1183/16000617.0057-2017 · Cited by 295 · cited 1×
“Long-term pirfenidone treatment requires surveillance for hepatotoxicity; however, it is generally well tolerated and tranilast has limited toxicities (Lancaster et al, 2017).”
BackgroundA key role for nox4 in epithelial cell death during development of lung fibrosis
Carnesecchi, S., Deffert, C., Donati, Y., Basset, O., Hinz, B., Preynat-Seauve, O., Guichard, C., Arbiser, J. L., Banfi, B., Pache, J.-C., et al. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3829 · Cited by 290
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311416259 · Cited by 284 · cited 1×
“Small molecule inhibitors targeting the TGFbRI have produced similar toxicity concerns including degenerative changes of heart valves and aorta and mucosal inflammation in the intestine (Anderton et al, 2011; Stauber et al, 2014).”
BackgroundNovel mechanisms for the antifibrotic action of nintedanib
Rangarajan, S., Kurundkar, A., Kurundkar, D., Bernard, K., Sanders, Y. Y., Ding, Q., Antony, V. B., Zhang, J., Zmijewski, J., & Thannickal, V. J. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0445oc · Cited by 238 · cited 1×
“Its effects on the fibroblast prevent ECM production and myofibroblast activation (Hostettler et al, 2014; Rangarajan et al, 2016).”
BackgroundThe perivascular origin of pathological fibroblasts
Di Carlo, S. E., & Peduto, L. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93558 · Cited by 164 · cited 1×
“The cellular origin of myofibroblasts in vivo has been debated extensively (Di Carlo & Peduto, 2018) with multiple candidates having been identified in the literature including epicardial or endothelial cells undergoing mesenchymal transition or migration of hematopoietic cells or pericytes into…”
BackgroundGenetic disorders coupled to ROS deficiency
O’Neill, S., Brault, J., Stasia, M.-J., & Knaus, U. G. (2015) · Redox Biology · doi:10.1016/j.redox.2015.07.009 · Cited by 164 · cited 1×
“However, NOX2 has an important role in the bactericidal effects of phagocytic cells, and hence, NOX2 deficiency results in granulomatous disease in both mice and humans, making it a challenging therapeutic target (O’Neill et al, 2015).”
BackgroundPatient selection in heart failure with preserved ejection fraction clinical trials
Kelly, J. P., Mentz, R. J., Mebazaa, A., Voors, A. A., Butler, J., Roessig, L., Fiuzat, M., Zannad, F., Pitt, B., O’Connor, C. M., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.043 · Cited by 139 · cited 1×
“This may begin to address some of the long-standing issues with patient selection for HFpEF clinical trials (Kelly et al, 2015) ensuring these therapies are targeted at the group of patients most likely to benefit.”
BackgroundGeorgianos, P. I., & Agarwal, R. (2019) · Diabetes Care · doi:10.2337/dc18-2207 · Cited by 130 · cited 1×
“…effects are also associated with SGLT2-Is including reduction in blood pressure, blood sugar and reduced renal RAAS expression in diabetic mice (Georgianos & Agarwal, 2019; Woods et al, 2019), and it is likely that the beneficial effects on cardiac health are multifactorial (Chin et al, 2019).”
BackgroundKanagala, P., Cheng, A. S. H., Singh, A., Khan, J. N., Gulsin, G. S., Patel, P., Gupta, P., Arnold, J. R., Squire, I. B., Ng, L. L., et al. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.11.031 · Cited by 126
Woods, T. C., Satou, R., Miyata, K., Katsurada, A., Dugas, C. M., Klingenberg, N. C., Fonseca, V. A., & Navar, L. G. (2019) · American Journal of Nephrology · doi:10.1159/000499597 · Cited by 124 · cited 1×
“…effects are also associated with SGLT2-Is including reduction in blood pressure, blood sugar and reduced renal RAAS expression in diabetic mice (Georgianos & Agarwal, 2019; Woods et al, 2019), and it is likely that the beneficial effects on cardiac health are multifactorial (Chin et al, 2019).”
BackgroundKovacs, R. J., Maldonado, G., Azaro, A., Fernández, M. S., Romero, F. L., Sepulveda-Sánchez, J. M., Corretti, M., Carducci, M., Dolan, M., Gueorguieva, I., et al. (2015) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9297-4 · Cited by 108 · cited 1×
“…window has been identified for the use of the TGFbRI inhibitor, galunisertib, in the treatment of myelodysplasia; however, this requires a stringent intermittent dosing schedule to avoid cardiac toxicity (Kovacs et al, 2015; Santini et al, 2019) and efficacy as an antifibrotic has not been tested.”
BackgroundBrennan, F. R., Cavagnaro, J., McKeever, K., Ryan, P. C., Schutten, M. M., Vahle, J., Weinbauer, G. F., Marrer-Berger, E., & Black, L. E. (2018) · mAbs · doi:10.1080/19420862.2017.1389364 · Cited by 70
Sedgwick, B., Riches, K., Bageghni, S. A., O’Regan, D. J., Porter, K. E., & Turner, N. A. (2014) · Cardiovascular Pathology · doi:10.1016/j.carpath.2014.03.004 · Cited by 52
Cited by
Spatial multi-omic map of human myocardial infarction
Kuppe, C., Ramirez Flores, R. O., Li, Z., Hayat, S., Levinson, R. T., Liao, X., Hannani, M. T., Tanevski, J., Wünnemann, F., Nagai, J. S., et al. (2022) · Nature · doi:10.1038/s41586-022-05060-x · Cited by 772
Selman, M., & Pardo, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101393 · Cited by 211
(2024) · doi:10.1007/s00395-024-01074-w · Cited by 59
Metadata
- Authors
- Sweeney, M., Corden, B., & Cook, S. A.
- Venue
- EMBO Molecular Medicine
- Published
- 2020-09-21
- Volume
- 12
- Issue
- 10
- Pages
- e10865-e10865
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3087152883
- Cited by
- 195
- References
- 61
- FWCI
- 15.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.